Organogenesis Holdings Inc.
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
About Organogenesis
Pharmaceutical Preparations, SIC 2834
Organogenesis Holdings Inc. develops, manufactures, and sells regenerative medicine solutions. The company operates across two primary commercial segments: Advanced Wound Care and Surgical & Sports Medicine. Its advanced wound care offerings include products such as Apligraf, Dermagraft, PuraPly, CYGNUS, VIA Matrix, Affinity, Novachor, NuShield, and SimpliMax, which treat acute and chronic wounds, including diabetic foot ulcers and venous leg ulcers. In the surgical and sports medicine segment, the company supplies products like PuraForce, NuShield, Cygnus Matrix, and PuraPly for soft tissue repair, tendon and ligament injuries, and open surgical wounds. Its customer base includes hospitals, outpatient wound care centers, government facilities, ambulatory surgery centers, and physician offices.
The company maintains its corporate headquarters and principal executive offices in Canton, Massachusetts. Its operations also include an additional manufacturing facility located in Smithfield, Rhode Island. Organogenesis conducts business within the United States, utilizing direct sales capabilities alongside independent sales agency networks to distribute its medical products to healthcare providers.
Summary of the business section of Organogenesis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Organogenesis Holdings Inc.
- Headquarters
- Canton, MA
- Address
- 85 Dan Road 02021
- Phone
- (781) 575-0775
- Website
- organogenesis.com
- Employees
- 854, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ORGO
- Exchange
- Nasdaq
- IPO date
- Oct 11, 2016
- Shares outstanding
- 129M, Jul 31, 2026
- Public float
- $299.40M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1661181
- CUSIP
- 68621F102
- ISIN
- US68621F1021
- LEI
- 549300RLC2O821TU6941
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gary S. Gillheeney | President and CEO, Director | 4,721,298 |
| Brian Grow | Chief Commercial Officer | 902,144 |
| Robert Cavorsi | Vice President, Strategy | 275,524 |
| Patrick Bilbo | Chief Operating Officer | 1,250,112 |
| Antonio S. Montecalvo | Vice President, Health Policy | 238,498 |
| David Francisco | Chief Financial Officer | 745,999 |
| Lori Freedman | Chief Admin. and Legal Officer | 1,023,643 |
| Patrick McGuire | Chief Accounting Officer | 16,965 |
| Michael Joseph Driscoll | Director | 225,707 |
| Arthur S. Leibowitz | Director | 291,014 |
| Jon L. Giacomin | Director | 241,026 |
| Gilberto Quintero | Director | 239,073 |
| Prathyusha Duraibabu | Director | 247,047 |
| Michele Ilene Korfin | Director | 239,073 |
| Garrett Lustig | Director | 125,742 |
| Glenn H. Nussdorf | Director | 11,903,172 |
| Alan A. Ades | Director | 169,834,688 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Gary S. Gillheeney, Sr. | $6.81M | $15.18M | $2.07M | $69 | $120 |
| FY2024 Gary S. Gillheeney, Sr. | $6.99M | $12.48M | $2.10M | $67 | $114 |
| FY2023 Gary S. Gillheeney, Sr. | $6.24M | $10.49M | $1.93M | $85 | $115 |
| FY2022 Gary S. Gillheeney, Sr. | $6.01M | -$1.04M | $1.30M | $56 | $111 |
| FY2021 Gary S. Gillheeney, Sr. | $4.43M | $6.31M | $1.28M | $192 | $125 |
| FY2020 Gary S. Gillheeney, Sr. | $2.54M | $5.10M | $975.08K | $157 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 854 employees worldwide.”
Corporate history
Events identified from SEC filings